romidepsin
romidepsin: sourced relationships with 1 company · 1 clinical trial tracked · 1 FDA decision.
romidepsin evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
What to watch
Prepared research question
How could romidepsin → BMY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) Reported 2009-11-05 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (1)
HERO Trial: Phase I Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents in Localized Bladder Cancer
Primary endpoint: Romidepsin Maximum Tolerated Dose (MTD)
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with romidepsin?
romidepsin has dated SEC/FDA relationship records for BRISTOL MYERS SQUIBB CO.
How many clinical trials involve romidepsin?
BioSniper tracks 1 clinical trial involving romidepsin.
What is romidepsin's latest FDA decision?
The most recent tracked FDA decision for romidepsin is Approval for 1 INDICATIONS AND USAGE ISTODAX is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy. ISTODAX is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy ( 1 )., dated November 5, 2009.